Spectral Medical Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Spectral Medical Inc.

EDTXF 1.100

-1.8%

Oct 28 10:15 AM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 PreviousNext

From: Sultan	10/13/2025 1:11:06 PM
	of 520

The topline results from the Tigris trial mark an important step forward in advancing sepsis care. As with earlier studies, the findings highlight the potential of PMX hemoadsorption in the correct patient population. Dr. Danielle Davison, Professor of Anesthesiology and Critical Care Medicine and Director of the Intensive Care Unit at George Washington University, shared her perspective: “Having participated in both EUPHRATES and Tigris, it is particularly satisfying to see these final results. We look forward to having this therapy available for our patients.” Dr. Davidson’s words emphasize both the continuity of rigorous research and the anticipation of making targeted therapies accessible to the patients who need them most. buff.ly

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 PreviousNext